K. Tolzien

发表

A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer

C. Nabhan, S. Sulo, T. Lestingi, 2013, British Journal of Cancer.

Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma.

C. Nabhan, D. Villines, A. Starr, 2012, Clinical lymphoma, myeloma & leukemia.

Efficacy and safety of clofarabine in relapsed and/or refractory non‐hodgkin lymphoma, including rituximab‐refractory patients

P. Venugopal, C. Nabhan, W. Fried, 2011, Cancer.

Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.

C. Nabhan, D. Villines, T. Lestingi, 2014, Clinical genitourinary cancer.

Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial.

C. Nabhan, S. Newman, J. Bitran, 2009, Urology.

Medical Oncology Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naïve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial

C. Nabhan, S. Newman, J. Bitran, 2009 .

Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.

C. Nabhan, J. Bitran, T. Lestingi, 2014, Clinical genitourinary cancer.

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

M. Egorin, C. Nabhan, D. Villines, 2012, British Journal of Cancer.

Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial

C. Nabhan, S. Hallmeyer, D. Milton, 2009, Journal of chemotherapy.

A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration – resistant prostate cancer patients responding to chemotherapy

C. Nabhan, J. Bitran, T. Lestingi, 2011, Avicenna Journal of Medicine.

Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer (CRPC).

C. Nabhan, J. Bitran, T. Lestingi, 2016, Journal of Clinical Oncology.

Overcoming chemotherapy resistance in patients (pts) with chemotherapy-failure, castration-resistant prostate cancer (CRPC) with sorafenib.

C. Nabhan, J. Bitran, T. Lestingi, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.